A thorough QT study with dalbavancin: A novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections

International Journal of Antimicrobial Agents

Volumn 45, Issue 4, 2015, Pages 393-398

  Dunne, Michael W ^a   Zhou, Meijian ^b   Darpo, Borje ^b,c  

^a Durata Therapeutics   (United States)

^b ICardiac Technologies   (United States)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

Acute bacterial skin and skin structure infection; Anti infective drug; Dalbavancin; QT; QTc prolongation; Thorough QT study

Indexed keywords

DALBAVANCIN; MOXIFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT; TEICOPLANIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; ADOLESCENT; ANALOGS AND DERIVATIVES; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PHYSIOLOGY; SKIN DISEASES, BACTERIAL; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SKIN DISEASES, BACTERIAL; TEICOPLANIN; YOUNG ADULT;

EID: 84925497753     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.12.021     Document Type: Article

References (21)

1. H.W. Boucher, M. Wilcox, G.H. Talbot, S. Puttagunta, A.F. Das, and M.W. Dunne Once-weekly dalbavancin versus daily conventional therapy for skin infection N Engl J Med 370 2014 2169 2179
2. International Conference on Harmonisation. ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drug. Questions & answers. Current version dated 21 March 2014. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-QAs-R2-Step4.pdf [accessed 2 October 2014].
3. International Conference on Harmonisation ICH harmonized tripartite guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs May, 2005 http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf (accessed 15 January 2015)
4. J.P. Couderc, C. Garnett, M. Li, R. Handzel, S. McNitt, and X. Xia Highly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines Ann Noninvasive Electrocardiol 16 2011 13 24
5. B. Darpo, A.A. Fossa, J.P. Couderc, M. Zhou, A. Schreyer, and M. Ticktin Improving the precision of QT measurements Cardiol J 18 2011 401 410
6. J. Zhang, and S.G. Machado Statistical issues including design and sample size calculation in thorough QT/QTc studies J Biopharm Stat 18 2008 451 467
7. J. Zhang Testing for positive control activity in a thorough QTc study J Biopharm Stat 18 2008 517 528
8. Y. Hochberg, and Y. Benjamini More powerful procedures for multiple significance testing Stat Med 9 1990 811 818
9. J.A. Florian, C.W. Tornoe, R. Brundage, A. Parekh, and C.E. Garnett Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies J Clin Pharmacol 51 2011 1152 1162
10. C.E. Garnett, N. Beasley, V.A. Bhattaram, P.R. Jadhav, R. Madabushi, and N. Stockbridge Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review J Clin Pharmacol 48 2008 13 18
11. C.W. Tornoe, C.E. Garnett, Y. Wang, J. Florian, M. Li, and J.V. Gobburu Creation of a knowledge management system for QT analyses J Clin Pharmacol 51 2011 1035 1042
12. A. Leighton, A.B. Gottlieb, M.B. Dorr, D. Jabes, G. Mosconi, and C. VanSaders Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers Antimicrob Agents Chemother 48 2004 940 945
13. R. Stahlmann, and H.M. Lode Risks associated with the therapeutic use of fluoroquinolones Expert Opin Drug Saf 12 2013 497 505
14. M.E. Murphy, K.P. Singh, M. Laurenzi, M. Brown, and S.H. Gillespie Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation Int J Tuberc Lung Dis 16 2012 144 149 (i-iii)
15. D. Guo, Y. Cai, D. Chai, B. Liang, N. Bai, and R. Wang The cardiotoxicity of macrolides: a systematic review Pharmazie 65 2010 631 640
16. R.C. Owens Jr. QT prolongation with antimicrobial agents: understanding the significance Drugs 64 2004 1091 1124
17. G.M. Keating Dihydroartemisinin/piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria Drugs 72 2012 937 961
18. US Food and Drug Administration FDA briefing document Bedaquiline Anti-Infective Drugs Advisory Committee meeting November 28, 2012 2012 http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm329257.htm (accessed 2 October 2014)
19. D.L. Stevens, A.L. Bisno, H.F. Chambers, E.P. Dellinger, E.J. Goldstein, and S.L. Gorbach Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America Clin Infect Dis 59 2014 147 159
20. S. Barriere, F. Genter, E. Spencer, M. Kitt, D. Hoelscher, and J. Morganroth Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects J Clin Pharmacol 44 2004 689 695
21. VIBATIV® (telavancin) US label Drugs@FDA 2014 http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022110s009lbl.pdf (accessed 2 October 2014)